Key drivers of biomedical innovation in cancer drug discovery
Abstract Discovery and translational research has led to the identification of a series of “cancer drivers”—genes that, when mutated or otherwise misregulated, can drive malignancy. An increasing number of drugs that directly target such drivers have demonstrated activity in clinical trials and are...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2014-11-01
|
| Series: | EMBO Molecular Medicine |
| Online Access: | https://doi.org/10.15252/emmm.201404596 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849234895939829760 |
|---|---|
| author | Margit A Huber Norbert Kraut |
| author_facet | Margit A Huber Norbert Kraut |
| author_sort | Margit A Huber |
| collection | DOAJ |
| description | Abstract Discovery and translational research has led to the identification of a series of “cancer drivers”—genes that, when mutated or otherwise misregulated, can drive malignancy. An increasing number of drugs that directly target such drivers have demonstrated activity in clinical trials and are shaping a new landscape for molecularly targeted cancer therapies. Such therapies rely on molecular and genetic diagnostic tests to detect the presence of a biomarker that predicts response. Here, we highlight some of the key discoveries bringing precision oncology to cancer patients. Large‐scale “omics” approaches as well as modern, hypothesis‐driven science in both academic and industry settings have significantly contributed to the field. Based on these insights, we discuss current challenges and how to foster future biomedical innovation in cancer drug discovery and development. |
| format | Article |
| id | doaj-art-17d88d49efbd41d3a9bc9c94bdd2a6a0 |
| institution | Kabale University |
| issn | 1757-4676 1757-4684 |
| language | English |
| publishDate | 2014-11-01 |
| publisher | Springer Nature |
| record_format | Article |
| series | EMBO Molecular Medicine |
| spelling | doaj-art-17d88d49efbd41d3a9bc9c94bdd2a6a02025-08-20T04:03:00ZengSpringer NatureEMBO Molecular Medicine1757-46761757-46842014-11-0171121610.15252/emmm.201404596Key drivers of biomedical innovation in cancer drug discoveryMargit A Huber0Norbert Kraut1Department of Dermatology and Allergic Diseases, Ulm UniversityOncology Research, Boehringer Ingelheim RCV GmbH & Co KGAbstract Discovery and translational research has led to the identification of a series of “cancer drivers”—genes that, when mutated or otherwise misregulated, can drive malignancy. An increasing number of drugs that directly target such drivers have demonstrated activity in clinical trials and are shaping a new landscape for molecularly targeted cancer therapies. Such therapies rely on molecular and genetic diagnostic tests to detect the presence of a biomarker that predicts response. Here, we highlight some of the key discoveries bringing precision oncology to cancer patients. Large‐scale “omics” approaches as well as modern, hypothesis‐driven science in both academic and industry settings have significantly contributed to the field. Based on these insights, we discuss current challenges and how to foster future biomedical innovation in cancer drug discovery and development.https://doi.org/10.15252/emmm.201404596 |
| spellingShingle | Margit A Huber Norbert Kraut Key drivers of biomedical innovation in cancer drug discovery EMBO Molecular Medicine |
| title | Key drivers of biomedical innovation in cancer drug discovery |
| title_full | Key drivers of biomedical innovation in cancer drug discovery |
| title_fullStr | Key drivers of biomedical innovation in cancer drug discovery |
| title_full_unstemmed | Key drivers of biomedical innovation in cancer drug discovery |
| title_short | Key drivers of biomedical innovation in cancer drug discovery |
| title_sort | key drivers of biomedical innovation in cancer drug discovery |
| url | https://doi.org/10.15252/emmm.201404596 |
| work_keys_str_mv | AT margitahuber keydriversofbiomedicalinnovationincancerdrugdiscovery AT norbertkraut keydriversofbiomedicalinnovationincancerdrugdiscovery |